

# Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Meningitis with Psychotic Symptoms

Xiaofei Cheng<sup>1</sup>, Qian Yang<sup>1</sup>, Zhewei Su<sup>1</sup>, Linyuan Sun<sup>1</sup>, Mei Wang<sup>1</sup>, and Mingli Li<sup>1</sup>

<sup>1</sup>Affiliation not available

January 30, 2024

## Abstract

**Introduction:** Anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated encephalitis is a demyelinating central nervous system disease, whose most common clinical manifestations are optic neuritis, myelitis and acute disseminated encephalitis. However, data on psychotic symptoms in anti-MOG antibody-associated meningitis are still limited. **Case description:** A 31-year-old female presented with headache, fever, thinking rupture, and dissociative amnesia. Enhancement of the pia mater was found in her magnetic resonance imaging. With antiviral therapies and anti-psychotic treatment, her symptoms didn't disappear until positive anti-MOG IgG antibody was found in the serum and she received steroid therapy. **Conclusion:** Psychotic symptoms may be the main manifestation of anti-MOG antibody-associated meningitis. Besides being caused by anti-neuronal antibodies against cell-surface antigens (such as anti-N-methyl-D-aspartate receptor antibodies) and intracellular antigens (such as anti-Hu antibodies), autoimmune psychosis could also occur due to anti-myelin antibodies against MOG. These findings may expand the understanding of this newly described autoimmune disease.

## **Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Meningitis with Psychotic Symptoms**

Xiaofei Cheng<sup>1</sup>, Qian Yang<sup>1</sup>, Zhewei Su<sup>1</sup>, Linyuan Sun<sup>1</sup>, Mei Wang<sup>1,2</sup>, Mingli Li<sup>\*1,2</sup>

1. Mental Health Center, West China Hospital, Sichuan University, Chengdu, China.

2. Sichuan Clinical Medical Research Center for Mental Disorders, Chengdu, China.

\*Correspondence: Mental Health Center, West China Hospital, Sichuan University, No.28 Dianxin

South Road, Chengdu 610041, China. +86-28-85423930 (Tel) limingli@wchscu.cn

**Keywords:** Psychosis, Myelin oligodendrocyte glycoprotein (MOG), Meningitis, Splitting

thoughts, Case report

1 **Abstract**

2 Introduction: Anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated  
3 encephalitis is a demyelinating central nervous system disease, whose most common clinical  
4 manifestations are optic neuritis, myelitis and acute disseminated encephalitis. However, data on  
5 psychotic symptoms in anti-MOG antibody-associated meningitis are still limited.

6 Case description: A 31-year-old female presented with headache, fever, thinking rupture, and  
7 dissociative amnesia. Enhancement of the pia mater was found in her magnetic resonance imaging.  
8 With antiviral therapies and anti-psychotic treatment, her symptoms didn't disappear until positive  
9 anti-MOG IgG antibody was found in the serum and she received steroid therapy.

10 Conclusion: Psychotic symptoms may be the main manifestation of anti-MOG  
11 antibody-associated meningitis. Besides being caused by anti-neuronal antibodies against  
12 cell-surface antigens (such as anti-N-methyl-D-aspartate receptor antibodies) and intracellular  
13 antigens (such as anti-Hu antibodies), autoimmune psychosis could also occur due to anti-myelin  
14 antibodies against MOG. These findings may expand the understanding of this newly described  
15 autoimmune disease.

16 **Introduction**

17 The acute onset of psychotic symptoms are common in various disorders such as  
18 schizophrenia, acute and transient psychotic disorder, and viral or bacterial encephalitis.  
19 Meanwhile, immunological causes have been detected to play an important role in psychosis,  
20 which were recently classified under autoimmune psychosis (AP). Significant findings were  
21 observed in AP cases: anti-neuronal antibodies against intracellular antigens (e.g. anti-Hu

1 antibodies) and cell-surface antigens (e.g. anti-N-methyl-D-aspartate receptor [NMDA-R])[2].  
2 MOG antibodies are reported present in 4.0%–7.5% of patients with NMDA-R encephalitis [3]. In  
3 such cases, psychotic symptoms can be accounted for by anti-NMDA-R encephalitis, in the  
4 context of which paranoid-hallucinatory symptoms are often the presenting complaint [4].  
5 However, the role of anti-MOG antibodies remained unclear, and they were usually not routine  
6 examination of patients with psychosis [1].

7 MOG is a membrane protein that is located on the surface of oligodendrocytes and in myelin  
8 sheaths [5]. Anti-MOG antibody-associated encephalitis is an immune-mediated inflammatory  
9 disease targeting MOG antigens in the central nervous system leading to demyelination.

10 Psychotic symptoms have been well studied in other demyelinating diseases. However,  
11 MOG-associated demyelinating disease may be distinct from acute disseminated  
12 encephalomyelitis, multiple sclerosis and neuromyelitis optica spectrum disorder [6], which has  
13 certain particular characteristics such as: (1) clinical manifestations of acute disseminated  
14 encephalomyelitis, optic neuritis, myelitis, and brainstem syndrome in most cases [7]; (2) imaging  
15 feature such as cortical lesions' hyper-intensity in fluid-attenuated inversion recovery (FLAIR) [8];  
16 (3) cerebrospinal fluid (CSF): white blood cell count has been elevated in more than 50% of CSF  
17 samples, and dysfunction of blood-CSF barrier was detected in 48% of the patients [9]; (4)  
18 electroencephalography (EEG): non-specific slow waves consistent with the location of cortical  
19 lesions; (5) electrophysiological investigations may reveal altered visually evoked potentials  
20 (VEPs) in patients with optic neuritis [10]; and (6) pathology: early lesions of demyelination, such  
21 as inflammatory changes present in the cortex and subcortex with microglial proliferation in  
22 subcortical white matter and peripheral vascular regions [11]. Consequently, anti-MOG

1 antibody-associated disorders must be identified as a separate disease entity. In 2018, the term  
2 MOG encephalomyelitis has been established by Jarius et al.[10], which is characterized by  
3 symptoms such as acute optic neuritis, myelitis, (brainstem) encephalitis, or any combination of  
4 them. Recently, its symptom spectrum has been expanded, including epileptic seizures,  
5 disturbance of consciousness, behavioral changes [10], as well as prolonged fever, which is an  
6 important component of the pediatric symptom complex [12]. It has now been described as MOG  
7 antibody-associated demyelinating disorders (MOGAD). However, the relationship of psychotic  
8 symptoms and MOGAD remains unknown.

9 We report one case of MOGAD with psychotic symptoms, aiming to discuss the possible  
10 relationship between them.

### 11 **Case description**

12 A 31-year-old female presented with headache and paroxysmal clouding of consciousness, as  
13 well as fever with 37.6 °C as the highest temperature for 3 days. She also lacked appetite and  
14 sleep, talking to herself at random. She underwent lumbar puncture in a local hospital, and her  
15 CSF nucleated leukocyte count was  $17 \times 10^6/L$  (reference range:  $0 - 8 \times 10^6/L$ ) without any  
16 other significant abnormal result, including magnetic resonance imaging (MRI). Thus, she was  
17 diagnosed with viral encephalitis and treated with antiviral therapy for 7 days. She regained  
18 consciousness; however, she developed new symptoms of splitting of thought (i.e., irrelevant and  
19 intricate answers for the physician's questions and thinking rupture, such as saying that the ozone  
20 layer has been totally destroyed) and dissociative amnesia (i.e., she could identify her parents, son,  
21 friends and physicians except for her husband) before admitted to our hospital. At neurological

1 examination, she showed features of meningeal irritation (particularly stiff neck), while other  
2 pathological signs were negative. Lumbar puncture was performed for the second time after  
3 admission. Her CSF pressure was 200/165 mmH<sub>2</sub>O. CSF analysis showed the nucleated leukocyte  
4 count decreased to  $2 \times 10^6/L$ , while other biochemistry indicators and routine CSF test results  
5 were still normal. Antibodies associated with autoimmune encephalitis in both CSF and serum  
6 were also detected: anti-NMDA-R, anti-leucine-rich glioma-inactivated protein 1, anti-  $\alpha$   
7 -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 1 and 2, anti-  $\gamma$  -aminobutyric  
8 acid-B receptor, anti-contactin-associated protein 2, anti-dipeptidyl-peptidase-like protein 6, and  
9 anti-IgLON family protein 5 antibodies. However, all the tests results were normal. Moreover,  
10 serological identification showed that her electrolyte, glycosylated hemoglobin, estrogen, cortisol,  
11 and thyroid, liver and kidney function were normal. Only pachymeningeal enhancement was  
12 observed on T2-weighted FLAIR MRI after gadolinium enhancement (Fig. 1A), with a  
13 disorganized alpha rhythm on EEG. She was treated with acyclovir (an antiviral drug) 500 mg  
14 every eight hours and paliperidone 6mg qd (once daily) for one week without any significant  
15 remission of psychotic symptoms. Subsequently, paliperidone was increased to 9 mg, and  
16 acyclovir was used in the next two weeks. Afterwards, she was discharged after totally recovering  
17 from dissociative amnesia but only partial remission of splitting of thought. Paliperidone 12 mg qd  
18 was continued. However, at the two-month follow-up, she still manifested splitting of thought and  
19 talking to herself. Clozapine (maximum dose of 100 mg) was prescribed for more than one month  
20 with paliperidone 12 mg qd; however, she had no significant improvements. The patient was  
21 readmitted, and lumbar puncture was performed for the third time. She was tested again for  
22 antibodies associated with autoimmune encephalitis and demyelinating disease in the central

1 nervous system and serum (anti-MOG antibodies, anti-aquaporin-1, anti-aquaporin-4, anti-myelin  
2 basic protein, anti-glial fibrillary acidic protein, and anti-flotillin-1/2), along with oligoclonal  
3 bands. The results showed no obvious abnormalities; however, anti-MOG IgG antibodies were  
4 positive in serum, with a titer of 1:10 (reference range: negative), as detected by live cell-based  
5 assays. Enhanced MRI showed no increase in the degree of meningeal enhancement compared  
6 with the previous one (Fig. 1B). Thus, she was diagnosed with anti-MOG antibody-associated  
7 meningitis and treated with intravenous methylprednisolone therapy at a dose of 20 mg/kg for 6  
8 consecutive days. Afterwards, prednisone acetate 55 mg was given to the patient orally with  
9 gradual dosage reduction. Clozapine 50 mg qn (every night) was also prescribed for 1 week,  
10 decreased to 25 mg qn for the next week, and then withdrawn. After the treatment, her thinking  
11 rupture remitted partly for 6 days; however, she recovered totally during the subsequent visit after  
12 two weeks. Enhanced MRI showed reduction in pachymeningeal enhancement in the third-month  
13 of follow-up (Fig. 1C). She did not present any symptoms and didn't relapse after the 4th month  
14 of follow-up. All important clinical events are showed in table 1.

## 15 **Discussion and conclusions**

16 In this report, we present the case of a patient diagnosed with anti-MOG antibody-associated  
17 meningitis, whose main clinical manifestation is thinking rupture. This is the third detailed case  
18 report of the patient with psychotic symptoms as well as anti-MOG antibodies (without comorbid  
19 anti-NMDA-R encephalitis) [1] and the first wherein immunotherapy was performed according to  
20 our literature search.

21 Previous studies reported that patients with anti-MOG antibodies encephalitis often presented

1 with comorbid anti-NMDA-R encephalitis [3]; moreover, approximately 9% of patients that had  
2 positive serum MOG-IgG antibodies were also positive for CSF anti-NMDAR-IgG antibodies  
3 [13]. Patients with anti-NMDA-R encephalitis was reported to have psychotic symptoms.  
4 However, patients with psychotic symptoms and have abnormal anti-MOG antibodies were rarely  
5 reported. To our knowledge, in previous studies, one case reported a patient with psychotic  
6 symptoms (intermittent visual hallucinations and paranoia), positive anti-MOG antibodies and  
7 anti-NMDA-R encephalitis [14]. The other two studies respectively reported two patients with  
8 anti-MOG antibody-associated psychosis, that were negative for anti-NMDA-R antibodies in both  
9 CSF and serum [1,15]. Two patients in the former study presented with acute-onset or chronic  
10 paranoid-hallucinatory syndrome [1]. While the latter study reported two pediatric patients with  
11 psychiatric disorders before or concomitant with recurrent alternating ON, which is the typical  
12 clinical manifestation of MOGAD [15]. Meanwhile, the patient in this case report was  
13 characterized with splitting of thought and dissociative amnesia (i.e., she could identify everyone  
14 except for her husband, which may be related to the fact that she accidentally found out that her  
15 husband was having an affair two weeks before she was became ill). This suggested the diversity  
16 of psychotic symptoms of anti-MOG antibody-associated encephalitis or meningitis. It also  
17 implied the importance of taking a detailed history of patients with acute-onset psychotic  
18 symptoms, especially including fever, headache, and unconsciousness.

19 The patient, who has symptoms such as splitting of thought and dissociative amnesia, didn't  
20 achieve complete remission with adequate doses of antipsychotic treatment, until she was treated  
21 with steroid pulse therapy. This implied the importance of immunotherapy in the treatment of  
22 anti-MOG antibody-associated encephalitis or meningitis with psychotic symptoms [16]. However,

1 the previous case which reported two patients with anti-MOG autoantibody-associated  
2 schizophreniform psychosis partly recovered due to treatment with risperidone, olanzapine, and  
3 valproate [1]. In that case, MRI analyses revealed no inflammatory lesions, but with pronounced  
4 intermittent rhythmic theta activity or disorganised alpha rhythm on EEG. However, one patient  
5 experienced recurring auditory hallucinations in stressful situations, while the other's negative  
6 symptoms persisted. Accordingly, patients with MOGAD seems to exhibit a rapid response to  
7 steroid therapy. Thus, we suggest that immunotherapy should be prescribed as soon as anti-MOG  
8 antibody encephalitis or meningitis with psychotic symptoms was confirmed.

9 Brain nervous system lesions related to MOG antibodies in previous cases mostly involved  
10 the brain parenchyma (including cerebral peduncles, pons, medulla oblongata, cerebellar  
11 hemispheres, and cerebellar peduncles), optic nerve, or spinal cord [17]. The main radiological  
12 sign was enhanced FLAIR signal in the cortical in patients with positive MOG antibody cortical  
13 encephalitis [18]. However, the patient in this case showed pachymeningeal enhancement instead  
14 of brain parenchymal lesions, with few focal neurological symptoms, which was rarely reported.  
15 This is similar to the case reported by Lin S et al. [19], in which brain MRIs revealed no  
16 parenchymal abnormality but slight enhancement of the leptomeninges. The usual reported  
17 prominent clinical manifestations of these patients include fever, headache, vomiting, and seizures.  
18 Nevertheless, the patient in this case showed psychotic symptoms except fever, as well as  
19 headache without seizures, which was unusual in MOG antibody-associated aseptic meningitis.  
20 Due to the atypical clinical features and CSF/MRI changes, MOG antibody-associated aseptic  
21 meningitis may be misdiagnosed as infectious encephalitis in the early stage (such as viral  
22 encephalitis), as seen in many cases. Therefore, this rare kind of MOGAD must be considered

1 especially when the patient presents with fever, headache, and mental disorders with  
2 meningitis-like image changes.

3 From a pathophysiological point of view, anti-MOG antibodies are considered to be  
4 pathogenic given their extracellular target being the myelin sheaths [20]. Furthermore, they cause  
5 experimental autoimmune encephalitis in animal models [21]. Moreover, the expression of MOG  
6 gene appears to be down-regulated in schizophrenia, which resides within a high-susceptibility  
7 locus for schizophrenia within the major histocompatibility complex (MHC) locus on  
8 chromosome 6p21.3 [22]. These findings may illustrate that anti-MOG antibodies may be  
9 responsible for some psychotic symptoms, or schizophrenia may be related to immunity in  
10 pathogenesis. However, these results should still be viewed with caution since there was no  
11 pathological evidence for demyelination, which leads to the uncertainty of whether encephalitis is  
12 caused by MOG antibodies or complications associated with other immune-mediated disease  
13 mechanisms.

14 Our findings prove the complexity of the clinical manifestations of anti-MOG  
15 antibody-associated diseases in patients with psychotic symptoms as the primary or main  
16 symptom. Thus, this report may expand our understanding of autoimmune psychosis. Besides  
17 being caused by anti-neuronal antibodies against cell-surface and intracellular antigens,  
18 autoimmune psychosis could also occur due to anti-myelin antibodies against MOG. More  
19 research is needed to understand the impact of anti-MOG antibody on psychosis.

## 20 **Abbreviations**

21 MOG: myelin oligodendrocyte glycoprotein; NMDA-R: N-methyl-D-aspartate receptor; AP:

1 autoimmune psychosis; FLAIR: fluid- attenuated inversion recovery; CSF: cerebrospinal fluid;  
2 EEG: electroencephalography; MRI: magnetic resonance imaging; MOGAD: Myelin  
3 oligodendrocyte glycoprotein antibody-associated demyelinating disorders.

#### 4 **Declarations**

#### 5 **Data availability statement**

6 The raw data is available from the corresponding author on reasonable request.

#### 7 **Ethics approval and consent to participate**

8 Written informed consent was obtained from the patient and her husband for the case report. This  
9 study protocol was reviewed and approved by West China Hospital Ethics Committee, approval  
10 number 941.

#### 11 **Consent for publication**

12 The patient and her husband received a complete description of the report and provided written  
13 informed consent to publish. A copy of the signed consent form is available for review by the  
14 editor of this journal.

#### 15 **Competing interests**

16 The authors declare that they have no competing interests.

#### 17 **Funding**

18 This study was supported by the National Nature Science Foundation of China (Grant  
19 NO.82071524 to ML), Science and Technology Project of Sichuan Province (2021YJ0238 to ML).

20 The above funding agencies had no role in the design of the study, collection, analysis, and  
21 interpretation of the data, or in the writing of the manuscript, but provided the publication cost.

1 **Author contributions**

2 XFC wrote the first draft of the manuscript. XFC, QY, LYS and ZWS collected the patient data.

3 LML made the contribution to the conception and revised the manuscript. All authors read and  
4 approved the final manuscript.

5 **Author details**

6 1. Mental Health Center, West China Hospital, Sichuan University, Chengdu, China.

7 2. Sichuan Clinical Medical Research Center for Mental Disorders, Chengdu, China.

8 **Acknowledgements**

9 We are appreciated to the patient in the study.

**References**

1. von Zedtwitz K, Matteit I, Michel M, Feige B, Runge K, Denzel D, et al. Anti-MOG autoantibody-associated schizophreniform psychosis. *Acta Neuropsychiatr.* 2022;34(1):47-54.

2. Pollak TA, Lennox BR, Müller S, Benros ME, Prüss H, Tebartz van Elst L, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. *The Lancet Psychiatry.* 2020;7(1):93-108.

3. Martinez-Hernandez E, Guasp M, Garcia-Serra A, Maudes E, Arino H, Sepulveda M, et al. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. *Neurology.* 2020;94(22):e2302-e10.

4. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology.* 2016;15(4):391-404.

5. Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. *P natl acad sci USA*. 2006;103(7):2280-5.
6. Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, et al. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. *J Neurol*. 2017;264(12):2420-30.
7. Lechner C, Baumann M, Hennes E-M, Rostásy K. MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. *Neuropediatrics*. 2017;49(01):003-11.
8. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. *Mult Scler*. 2013;19(10):1261-7.
9. Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hummert MW, Ringelstein M, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. *J Neuroinflammation*. 2020;17(1):261.
10. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. *J Neuroinflammation*. 2018;15(1):134.
11. Ikeda T, Yamada K, Ogawa R, Takai Y, Kaneko K, Misu T, et al. The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: A case report. *J Neurol Sci*. 2018;392:113-5.

12. Udani V, Badheka R, Desai N. Prolonged Fever: An Atypical Presentation in MOG Antibody-Associated Disorders. *Pediatr Neurol.* 2021;122:1-6.
13. Ding J, Li X, Tian Z. Clinical Features of Coexisting Anti-NMDAR and MOG Antibody-Associated Encephalitis: A Systematic Review and Meta-Analysis. *Front Neurol.* 2021;12:711376.
14. Zhou J, Tan W, Tan SE, Hu J, Chen Z, Wang K. An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis. *J Neuroimmunol.* 2018;320:107-10.
15. Singh B, Cruz-Flores S, Chaudhry MR, Piriawat P, Ponce CP. Psychiatric manifestations of anti-MOG antibody disease. *Neuroimmunology Reports.* 2022;2.
16. Whittam DH, Karthikeyan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. *J Neurol.* 2020;267(12):3565-77.
17. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. *J Neuroinflammation.* 2016;13(1):280.
18. Tian F, Liu X, Yang C, Wang B, Song Z, Zhang Y. MOG antibody-positive cerebral cortical encephalitis: Two case reports and literature review. *Int J Dev Neurosci.* 2021;81(4):342-51.
19. Lin S, Long W, Wen J, Su Q, Liao J, Hu Z. Myelin oligodendrocyte glycoprotein antibody-associated aseptic meningitis without neurological parenchymal lesions: A novel phenotype. *Mult Scler Relat Disord.* 2022;68:104126.

20. Lalive PH, Molnarfi N, Benkhoucha M, Weber MS, Santiago-Raber M-L. Antibody response in MOG35 – 55 induced EAE. *Journal of Neuroimmunology*. 2011;240-241:28-33.
21. Fu J, Peng L, Yang Y, Xie Y, Li Z, Rong B. Case report: Overlapping syndrome mimicking infectious meningoencephalitis in a patient with coexistent MOG, NMDAR, mGluR5 antibody positivity. *Frontiers in Immunology*. 2022;13.
22. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *The Lancet*. 2003;362(9386):798-805.